The International Journal of Rheumatic Diseases, published by WILEY, serves as a crucial platform for disseminating high-quality research and advancements in the field of rheumatology. With an ISSN of 1756-1841 and an E-ISSN of 1756-185X, this journal has established itself within the academic community since its inception in 2008, and it is set to continue until at least 2024. Positioned in the Q3 category of rheumatology, the journal holds a significant rank of #38 out of 73 in its field according to Scopus, showcasing its growing influence despite the competitive environment. The absence of Open Access reflects a traditional scholarly publishing model, allowing for meticulous peer-review processes to ensure the rigor and reliability of published studies. This journal aims to foster innovative research, critical reviews, and clinical studies, thereby contributing to a deeper understanding of rheumatic diseases and enhancing patient care. The dedicated readership, including researchers, healthcare professionals, and students, will find valuable insights into the latest findings and methodologies relevant to rheumatology in the journal's comprehensive articles.

Nature Reviews Rheumatology is a premier academic journal published by NATURE PORTFOLIO, dedicated to the field of rheumatology. With an impressive impact factor reflecting its high citation rate and relevance within the scientific community, it ranks in the Q1 category for rheumatology, showcasing its essential role in disseminating cutting-edge research and reviews. The journal serves as a vital resource for researchers, clinicians, and students alike, presenting comprehensive articles that cover the latest developments, therapeutic advancements, and emerging trends in rheumatic diseases. With access options, including open access, it ensures that valuable insights are within reach for all stakeholders in the field. Situated in the United Kingdom and intersecting with a global audience, Nature Reviews Rheumatology stands as an authoritative voice, fostering education and innovation to improve patient outcomes and enhance the understanding of rheumatological conditions.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.

Welcome to the Indian Journal of Rheumatology, a premier scholarly platform dedicated to advancing research and clinical practice in the field of rheumatology. Published by SAGE Publications Inc., this journal has been providing open access to its valuable content since 2006, promoting the dissemination of knowledge in India and beyond. As a voice in the rheumatology community, the journal addresses a wide range of topics including epidemiology, diagnostics, treatment strategies, and patient care in rheumatic diseases. Despite being classified in the Q4 category of the 2023 Scopus rankings, with a current position of Rank #57 among 73 journals, it serves as an essential resource for researchers, healthcare professionals, and students seeking to stay updated with the latest developments. The journal is committed to fostering scholarly dialogue and facilitating access to research that influences practice and improves patient outcomes in rheumatologic care.

AKTUELLE RHEUMATOLOGIE is a prominent German journal published by GEORG THIEME VERLAG KG, dedicated to advancing the field of rheumatology. Since its inception in 1978, this peer-reviewed journal has been a vital resource for professionals, researchers, and students engaged in the study and treatment of rheumatic diseases. With an ISSN of 0341-051X and an E-ISSN of 1438-9940, the journal provides a platform for sharing groundbreaking research, clinical studies, and reviews. Although classified in the fourth quartile (Q4) of rheumatology journals and ranked 67 out of 73 in its category according to Scopus, AKTUELLE RHEUMATOLOGIE continues to contribute to the discourse in rheumatology. Its comprehensive coverage of recent advancements and innovative approaches makes it an essential publication for anyone interested in the latest developments in the field.

The Egyptian Rheumatologist is a peer-reviewed Open Access journal dedicated to advancing the field of rheumatology. Published by Elsevier since 2011, the journal aims to disseminate high-quality research, clinical innovations, and reviews that cover a wide range of topics related to autoimmune diseases, arthritis, and musculoskeletal disorders. With an ISSN of 1110-1164 and an E-ISSN of 2090-2433, it has achieved a respectable rank of #50 out of 73 in the medicine/rheumatology category according to Scopus, positioning it in the 32nd percentile among its peers. Operating from its base in Amsterdam, Netherlands, the journal provides an accessible platform for researchers, professionals, and students, encouraging a collaborative exchange of cutting-edge knowledge that is essential for the ongoing developments in rheumatologic care and research. The Open Access model ensures that critical findings and advancements are available to a global audience, fostering further research and education within this vital field.

Pediatric Rheumatology is a leading peer-reviewed open access journal published by BMC, dedicated to disseminating high-quality research in the field of pediatric rheumatology. Since its inception in 2007, the journal has established itself as a vital resource for healthcare professionals, researchers, and students focused on pediatric immunology, rheumatology, and child health, maintaining an impressive Q1 ranking in Pediatrics and Q2 in Immunology and Allergy as well as Rheumatology for 2023. It is recognized for its impact on advancing knowledge and clinical practice, with significant contributions noted in various studies and case reports. With access options that embrace the ethos of open science, all articles published in Pediatric Rheumatology are freely available, promoting collaborative research and discussion among practitioners across the globe. The journal welcomes submissions that encapsulate innovative research, clinical trials, and reviews that address both current challenges and advancements within the pediatric rheumatology landscape.

RMD Open, published by the BMJ Publishing Group, is a leading open-access journal that has made significant contributions to the fields of Immunology, Immunology and Allergy, and Rheumatology since its inception in 2015. With an impressive Q1 ranking in these categories for 2023, the journal has established itself as an essential platform for the dissemination of high-quality research, case studies, and reviews that advance understanding and treatment strategies in these critical areas of health. As an open-access publication, RMD Open ensures that its content is freely accessible to a global audience, promoting collaboration and knowledge sharing among researchers, clinicians, and students. Based in the United Kingdom at the British Medical Association House, RMD Open is not only dedicated to improving patient care but also to fostering innovative research and discussions in the rapidly evolving landscape of rheumatic diseases.

ZEITSCHRIFT FUR RHEUMATOLOGIE, published by Springer Heidelberg, serves as a vital platform in the field of rheumatology, providing researchers, clinicians, and students with cutting-edge findings and discussions related to the diagnosis, treatment, and management of rheumatic diseases. Since its inception in 1974 and continuing until 2024, this journal retains its commitment to disseminating significant scientific work within this specialized domain. Although it is currently categorized in the Q4 quartile for Rheumatology and ranks 47 out of 73 in Scopus, reflecting its burgeoning presence, the journal is dedicated to evolving and gaining prominence in the academic community. By offering valuable insights and fostering scholarly discourse, ZEITSCHRIFT FUR RHEUMATOLOGIE plays a crucial role in advancing rheumatology research and enhancing patient care practices worldwide. The journal presents an opportunity for its readers to engage with contemporary studies and enrich their understanding of rheumatic ailments.

BMC Rheumatology is a vital open-access journal that has been disseminating high-quality research in the field of rheumatology since its inception in 2017. Published by Springer Nature, this journal provides a platform for original research, reviews, and clinical studies that advance the understanding and treatment of rheumatic diseases. With a commendable impact factor and ranked in the second quartile (Q2) for Rheumatology as of 2023, BMC Rheumatology exemplifies expertise, contributing significantly to the medical community's dialogue. Researchers, professionals, and students will find valuable insights within its pages, as it caters to a diverse audience through its commitment to open-access publishing, facilitating knowledge sharing without barriers. Based in the United Kingdom and indexed in Scopus, the journal continues to thrive with a steady convergence of academic excellence through 2024, making it an indispensable resource for those dedicated to advancing rheumatological science.